标题
Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
作者
关键词
-
出版物
ACS Omega
Volume 6, Issue 25, Pages 16259-16265
出版商
American Chemical Society (ACS)
发表日期
2021-06-15
DOI
10.1021/acsomega.1c01755
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lumasiran: First Approval
- (2021) Lesley J. Scott et al. DRUGS
- Inclisiran: First Approval
- (2021) Yvette N. Lamb DRUGS
- Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
- (2020) Daniel P. Judge et al. CARDIOVASCULAR DRUGS AND THERAPY
- Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid (siRNA), Givosiran, in Patients with Acute Hepatic Porphyria
- (2020) Sagar Agarwal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Givosiran: First Approval
- (2020) Lesley J. Scott DRUGS
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
- (2020) Alexandre J. Debacker et al. MOLECULAR THERAPY
- Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
- (2020) Manisha Balwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
- (2020) Christopher R Brown et al. NUCLEIC ACIDS RESEARCH
- Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
- (2019) Eliane Sardh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current and innovative emerging therapies for porphyrias with hepatic involvement
- (2019) Antonio Fontanellas et al. JOURNAL OF HEPATOLOGY
- Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
- (2019) Yanfeng Wang et al. Expert Opinion on Drug Metabolism & Toxicology
- Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
- (2019) Jessica E. Sutherland et al. Nucleic Acid Therapeutics
- Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo
- (2018) Vivek K. Sharma et al. BIOCONJUGATE CHEMISTRY
- The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
- (2018) Maja M. Janas et al. TOXICOLOGIC PATHOLOGY
- Therapeutic Oligonucleotides: State of the Art
- (2018) C.I. Edvard Smith et al. Annual Review of Pharmacology and Toxicology
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
- (2017) Michael Tanowitz et al. NUCLEIC ACIDS RESEARCH
- Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
- (2017) Karsten Schmidt et al. NUCLEIC ACIDS RESEARCH
- Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes
- (2016) Garth A. Kinberger et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
- (2016) Abigail Liebow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys
- (2016) Rosie Z. Yu et al. Nucleic Acid Therapeutics
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
- (2016) Rosie Z Yu et al. Molecular Therapy-Nucleic Acids
- siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes
- (2015) Shigeo Matsuda et al. ACS Chemical Biology
- Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
- (2015) Anisha A. D'Souza et al. JOURNAL OF CONTROLLED RELEASE
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Liver as a target for oligonucleotide therapeutics
- (2013) Alfica Sehgal et al. JOURNAL OF HEPATOLOGY
- The Asialoglycoprotein Receptor Regulates Levels of Plasma Glycoproteins Terminating with Sialic Acid α2,6-Galactose
- (2008) Lindsay M. Steirer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started